kabutan

KISSEI PHARMA, Ordinary Profit Forecast for the Fiscal Year Revised Downward to a Loss

Tue Jul 29, 2025 3:30 pm JST Earnings

4547 KISSEI PHARMACEUTICAL CO.,LTD. 【J-GAAP】

Earnings Report

KISSEI PHARMACEUTICAL CO.,LTD. <4547> [TSE Prime] announced its financial results after the market closed on July 29th (15:30). The consolidated ordinary profit for the first quarter of the fiscal year ending March 2026 (April to June) was 2.91 billion yen, a 1.4% increase compared to the same period last year.

However, the full-year forecast for consolidated ordinary profit/loss has been revised downward from an expected profit of 7.40 billion yen to a loss of 2.60 billion yen (compared to a profit of 6.97 billion yen in the previous period), turning to a loss outlook.

At the same time, the April to September period (first half) consolidated ordinary profit/loss has been revised downward from an expected profit of 3.10 billion yen to a loss of 6.90 billion yen (compared to a profit of 2.23 billion yen in the same period of the previous year), turning to a loss outlook.

In the most recent three-month period, from April to June (1Q), the operating profit margin decreased from 10.2% in the same period last year to 9.5%.

Kabutan News

Actual Results

Accumulated Results 1st Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Jun, 2023 19,313 1,633 2,712 3,265 71.0 78.3 Jul 31, 2023 J-GAAP
Apr - Jun, 2024 21,164 2,158 2,876 4,106 92.9 128.6 Jul 30, 2024 J-GAAP
Apr - Jun, 2025 22,191 2,108 2,915 4,519 107.9 ー Jul 29, 2025 J-GAAP
YoY +4.9% -2.3% +1.4% +10.1% +16.1%

Guidance Update

First Half Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2025 Prev 44,300 2,300 3,100 6,200 149.6 60 May 7, 2025 J-GAAP
Apr - Sep, 2025 New 44,300 -7,700 -6,900 6,200 149.6 60 Jul 29, 2025 J-GAAP
Revision Rate 0.0% － － 0.0% 0.0%

Full Year Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2026 Prev 91,500 6,000 7,400 12,300 296.7 120 May 7, 2025 J-GAAP
Mar, 2026 New 91,500 -4,000 -2,600 12,300 296.7 120 Jul 29, 2025 J-GAAP
Revision Rate 0.0% － － 0.0% 0.0%

Current Period Guidance

H1 Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2024 42,466 1,781 2,237 5,249 118.8 45 Nov 5, 2024 J-GAAP
Apr - Sep, 2025 Guidance 44,300 -7,700 -6,900 6,200 149.6 60 Jul 29, 2025 J-GAAP
YoY +4.3% － － +18.1% +26.0%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 75,579 4,017 6,142 11,160 246.6 82 May 7, 2024 J-GAAP
Mar, 2025 88,330 5,773 6,974 11,961 274.2 100 May 7, 2025 J-GAAP
Mar, 2026 Guidance 91,500 -4,000 -2,600 12,300 296.7 120 Jul 29, 2025 J-GAAP
YoY +3.6% － － +2.8% +8.2%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Apr - Jun, 2024 21,164 2,158 2,876 4,106 92.9 10.2 Jul 30, 2024 J-GAAP
Jul - Sep, 2024 21,302 -377 -639 1,143 25.9 -1.8 Nov 5, 2024 J-GAAP
Oct - Dec, 2024 23,203 2,457 3,061 3,591 81.8 10.6 Feb 3, 2025 J-GAAP
Jan - Mar, 2025 22,661 1,535 1,676 3,121 71.6 6.8 May 7, 2025 J-GAAP
Apr - Jun, 2025 22,191 2,108 2,915 4,519 107.9 9.5 Jul 29, 2025 J-GAAP
YoY +4.9% -2.3% +1.4% +10.1% +16.1%

Related Articles